Novartis Pursues Intractable Oncology Targets With Antares’ Help
Scorpion spin-out Antares will get $105m up front to advance its own pipeline while deploying a covalent binding technology in discovery effort against Novartis-picked targets.
Scrip - June 24, 2026

Vertanical Chief Determined To Move The Pain Dial
Exilby has just been approved in Germany and Austria for chronic low back pain and serial entrepreneur Clemens Fischer tells Scrip the German-based group can turn the cannabis-derived drug into a blockbuster on its own.
Scrip - June 24, 2026

RQ Bio Raises $115m Series A To Advance Long-Acting Influenza Antibody RQB01
The financing provides fresh capital for the firm's next stage of growth, including the progression of RQB01 toward clinical development.
Scrip - June 24, 2026

HepQuant SHUNT Wins FDA Premarket Approval For Variceal Screening In Compensated Cirrhosis
The FDA has granted premarket approval to HepQuant SHUNT, a blood-based liver function test that quantifies the risk of large esophageal varices in compensated cirrhosis patients, potentially reducing unnecessary endoscopies.
Medtech Insight - June 24, 2026

FTC Warns Stelara Ruling Could Weaken Pharma Antitrust
The US FTC believes CareFirst need not prove J&J specifically intended to harm biosimilar competition in its Stelara monopoly case, warning the lower court’s standard could blunt pharma antitrust enforcement.
Generics Bulletin - June 24, 2026

India Reopens Consultation On Medical Device Import Exemption List
India is reviewing which medical devices should remain exempt from domestic procurement requirements — and the gap between domestic manufacturers who want the list cut and importers who warn against restricting patient access is wider than the consultation process might suggest.
Medtech Insight - June 24, 2026

Ollin Raises Series B Round To Move OLN324 Into Phase III Development
The company is planning a Phase III program for the VEGFxAng2-directed bispecific in diabetic macular edema and wet age-related macular degeneration.
Scrip - June 24, 2026

‘It’s A Question Of How This New Game Will Be Played’ – Adapting To The EU Pharma Package
While the new EU pharma legislation package has been broadly well-received by industry, it remains to be seen how certain elements will be implemented in practice. Panelists shared their views at Medicines for Europe’s legal affairs conference in Athens earlier this month.
Generics Bulletin - June 24, 2026

India’s Generics Giants Could Ease US Cancer Shortage
The FDA is seeking potential Indian suppliers of ifosfamide after a US supply disruption hit availability of the cancer drug, with the IDMA saying India has the capacity to help if companies meet US quality requirements.
Generics Bulletin - June 24, 2026

Alzheimer’s Experts At BIO 2026 Said Biomarkers Are The Biggest Barrier And Opportunity
A panel of venture philanthropists, VC, pharma exec and biotech leader discussed diversifying investments and pipeline to accelerate progress in Alzheimer’s agreed that the biggest bottleneck today is biomarkers.
Medtech Insight - June 24, 2026

FDA-Cleared Digital Health Tools Pass 1,900, With AI Driving Almost All The Growth
FDA-cleared digital health tools have passed 1,900, with AI-enabled devices accounting for 73 of the 87 net additions this quarter as the agency signals it will begin tracking foundation models and large language models (LLMs).
Medtech Insight - June 24, 2026

2027 Cost Environment Not A Temporary Spike, Says PwC
US commercial medical cost trend will run at 9% in 2027, PwC projects, with AI-enabled documentation now ranked the leading driver.
In Vivo - June 24, 2026

Peptides Part Of Diet ‘Our Whole Life’ But Do They Qualify As Dietary Ingredients Under DSHEA?
Pharmaceutical firms protecting investments in GLP-1s and regulators considering whether supplements containing peptides are unapproved drugs should know that peptides are ingredient options under DSHEA as well as staples of ordinary diets for centuries.
HBW Insight - June 24, 2026

Supplement Firms Begin To Expect Enforcement Against Peptide Ingredients ‘Around The Corner’
Supplement marketers “really feel like we're going to open the paper or turn on the radio one day and find out our products are non-compliant,” says Jeff Cohen, co-founder of the American Peptide Association.
HBW Insight - June 24, 2026

BIO Notebook: MFN, Potential China Deals Ban Weigh Heavily On Dealmaking
The BIO annual meeting continues with pharma execs reacting to potential legislation blocking deals with China, a look at how most favored nation pricing policies are affecting deal terms, NVIDIA's new agentic AI toolkit for life sciences, and FDA officials discuss hiring efforts.
Scrip - June 24, 2026

Givaudan Launches Slow-Release Scent Technology For Hair
Swiss fragrance and flavors company Givaudan launches Aquamelon, an extended-release fragrance molecule for hair care products.
HBW Insight - June 24, 2026